Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2023-07-28 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a communication addressed to stock exchanges (NSE and BSE) regarding the publication of the company's financial results for the quarter ended June 30, 2023. It references Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which govern disclosures related to financial results. The document includes a newspaper advertisement of the financial results, indicating it is an announcement of the results being published rather than the full financial report itself. The length is about 15,000 characters, but the content is primarily an announcement and a copy of the advertisement, not the detailed financial statements or management discussion. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of the financial results publication, not the full quarterly report (IR) or earnings release (ER).
2023-07-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated July 27, 2023, addressed to stock exchanges, informing that the audio recording of the company's Q1 FY24 conference call with investors and analysts is available on the company's website. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, indicating a regulatory compliance announcement. The document does not contain the transcript or detailed financial data itself, only a notice about the availability of the conference call recording. According to the rules, such announcements about availability of conference call recordings are classified as Regulatory Filings (RNS), not as Call Transcripts (CT) or Interim Reports (IR). The document length is only 1461 characters, which is short and consistent with an announcement rather than a full report or transcript.
2023-07-27 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Earnings Presentation on Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2023" and includes detailed financial data such as revenue, EBITDA, PAT, and operational highlights for Q1 FY24. It also contains management commentary and forward-looking statements typical of earnings presentations. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis for the quarter. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not a brief earnings release (ER) since it includes detailed financials and management commentary, nor is it a full interim report (IR) as it is presented as a presentation document. Therefore, the correct classification is Investor Presentation (IP).
2023-07-27 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated July 27, 2023, announcing the unaudited financial results for the quarter ended June 30, 2023. It contains summarized financial highlights such as revenue, EBITDA, PAT, and EPS for Q1 FY 2023-24 compared to Q1 FY 2022-23. The document is relatively short (5432 characters) and is styled as a press release rather than a comprehensive financial report. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it serves as an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q1 2024
2023-07-27 English
Record Date
Board/Management Information Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Dr. Lal PathLabs Limited regarding the outcome of a Board Meeting held on July 27, 2023. It includes multiple corporate governance updates such as the convening of the 29th Annual General Meeting (AGM), declaration of interim dividend, appointment of additional independent directors, appointment of secretarial auditors, and grant of ESOPs to employees. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes annexures with detailed disclosures about director appointments and ESOP plans. The content focuses on board decisions and management changes rather than financial results or full reports. It is not a full annual report, audit report, earnings release, or financial statement. It is not a proxy solicitation or voting results announcement. The primary focus is on board and management information, including appointments and governance-related disclosures. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2023-07-27 English
Record Date
Board/Management Information Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Dr. Lal PathLabs Limited dated July 27, 2023. It reports the outcome of a Board Meeting including approval of convening the 29th Annual General Meeting (AGM), declaration of interim dividend, appointment of additional independent directors, appointment of secretarial auditors, and grant of ESOPs to employees. The document includes disclosures required under SEBI Listing Regulations and SEBI circulars, with annexures providing detailed information about the appointments and ESOPs. There are no financial statements or comprehensive financial performance data presented, nor is this a transcript or presentation. The document primarily announces board decisions and appointments, which aligns with the category of Board/Management Information (MANG). It is not an Annual Report, Earnings Release, or any other report type. Therefore, the correct classification is MANG with high confidence.
2023-07-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.